Edgewood, MD – Nutramax Laboratories Consumer Care, Inc. is pleased to share the results of a study published by Fahey, et al. in the journal Nutrients describing the bioavailability (absorption and excretion) and pharmacodynamics (the molecular effects) of Avmacol®, a nutraceutical that supports sulforaphane production.
Sulforaphane is a phytochemical that turns on genes that have powerful health benefits. Sulforaphane is made when its precursor glucoraphanin is converted by the enzyme myrosinase. Both precursor and enzyme are present in broccoli and other cruciferous vegetables and are provided in Avmacol. In the laboratory, sulforaphane conversion has been shown to be impacted by pH. At a low pH ("acidic pH"), an inactive form called sulforaphane nitrile is made suggesting an acidic stomach would decrease the amount of sulforaphane available to be used by the body.
Researchers at the Johns Hopkins School of Medicine examined whether gastric acidity effected the bioavailability of sulforaphane when Avmacol was taken in the presence or absence of a medicine called a proton pump inhibitor (PPI). A PPI reduces acid production and is one of the more frequently prescribed medicines in the U.S.
In a clinical trial, 16 participants took Avmacol with or without a PPI. Dr. Jed Fahey and his research team examined the levels of SFN excreted in the urine over a 24-hour period and determined that Avmacol supported robust sulforaphane bioavailability. Additionally, researchers showed that taking Avmacol resulted in an increase in the expression of genes that help protect cells against oxidative stress.
Avmacol was developed by the dedicated scientists at Nutramax Laboratories Consumer Care, Inc., including a leading sulforaphane researcher, Dr. Brian Cornblatt, who has worked with this unique phytochemical in the lab and in clinical studies for over a decade. Dr. Cornblatt remarked, “We developed an Avmacol tablet to help maintain the integrity of glucoraphanin and active myrosinase enzyme. Most other products on the market are in a capsule. Capsules have inherent water content making the glucoraphanin precursor and myrosinase enzyme more vulnerable to degradation. This study allowed us to assess several important things at once: bioavailability of a tablet containing both glucoraphanin and active myrosinase enzyme when administered with a PPI, and pharmacodynamic changes after a single dose.”
Dr. Grace Cornblatt, Director of Nutramax Laboratories’ Translational Research Laboratory, whose team studies the molecular mechanisms of action of company products, noted, “This is the first published study assessing bioavailability that provides direct evidence that ingredients in Avmacol can be converted to sulforaphane in the human body. We are also excited that the clinical trial showed an effect on the expression of cytoprotective genes confirming what we have seen in the laboratory for many years.” According to Dr. Troy Henderson, President and CEO of Nutramax Laboratories Consumer Care, Inc., “this clinical study, along with more than a dozen others, are being conducted in the U.S. and internationally using Avmacol and exemplify our company’s dedication to science and creating efficacious products that promote health and wellness.”
About Nutramax Laboratories Consumer Care, Inc.
Nutramax Laboratories Consumer Care, Inc. has locations in Edgewood, Maryland, and Lancaster, South Carolina and is focused on researching and developing products to promote consumer health. Since its inception in 1992, the Christian-based company has been committed to developing high quality products that are backed by sound science and extensive research. Each Nutramax Laboratories Consumer Care, Inc. product undergoes more than 80 quality checks.
To learn more visit www.Avmacol.com.